APRE stock forecast, quote, news & analysis
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers... Show more
Why Aprea Therapeutics (APRE) Stock Is Down -31% in the Last 30 Days
Key Takeaways
- Aprea Therapeutics (APRE) shares declined roughly 31% over the trailing 30 days, falling from about $0.70 to about $0.48 per share.
- The decline occurred even as Ladenburg Thalmann initiated coverage with a Buy rating and a $2.00 price target in mid-October.
- The move reflects a retracement from a sharp, high-volume advance in late August, alongside sustained pressure on pre-revenue, clinical-stage biotechnology names.
- Aprea is advancing APR-1051, an oral WEE1 kinase inhibitor, with a Phase 1 data update from the ACESOT-1051 trial anticipated at a medical meeting in Q4 2026.
- The company reported cash of roughly $41.2 million as of June 30, 2026, which it believes funds operations into the first quarter of 2028.
- For additional detail, explore Price Targets, Earnings, and Forecast pages for APRE.
- You can also explore Trending AI Robots to see how automated trading strategies are positioned across the market.
Aprea Therapeutics (APRE) Company Overview and Market Position
Aprea Therapeutics is a clinical-stage precision medicine oncology company headquartered in Doylestown, Pennsylvania. The company develops targeted, small-molecule therapies designed to exploit cancer-specific genetic vulnerabilities through synthetic lethality, aiming to kill tumor cells while minimizing damage to healthy tissue. Its lead program, APR-1051, is an oral, small-molecule inhibitor of WEE1 kinase in a Phase 1 trial (ACESOT-1051) for patients with biomarker-defined advanced solid tumors. A second program, ATRN-119, is a macrocyclic ATR inhibitor that the company is evaluating in potential combination approaches. Investors follow APRE for its pipeline catalysts, including dose-escalation data and expansion into uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.
Aprea Therapeutics (APRE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, APRE declined approximately 31%, moving from a closing price of $0.7001 on October 2, 2026, to $0.4846 on October 30, 2026. The month was marked by a steady downtrend punctuated by a sharp single-session drop in late October, before a modest partial recovery into month-end.
The broader quarterly trend tells a similar but more volatile story. From a closing level of $0.5977 in early August, the stock is down roughly 19% over the trailing three months. Within that window, however, shares surged in late August to a closing high near $0.98 with an intraday peak above $1.10 on unusually heavy volume, before giving back those gains through September and October. The result is a stock that remains well below its late-summer peak despite the positive analyst coverage received during the month.
What Drove APRE Stock Price in the Last 30 Days
Several company-specific developments occurred during October, yet the share price moved lower overall. On October 14, Ladenburg Thalmann initiated coverage of Aprea with a Buy rating and a $2.00 price target. Around the same period, the company participated in the 2026 Maxim Growth Summit and a Regional Biotechnology Conference, and on October 16 it announced a pre-ESMO virtual panel titled "The State of WEE1 Inhibition in Precision Oncology," held on October 20.
Despite these engagement efforts, the stock's downward trajectory suggests that selling pressure outweighed the positive catalysts. The decline appears to reflect a continued unwind of the late-August advance, coupled with broader weakness in small-cap and pre-revenue biotechnology equities, where investor risk appetite can shift quickly absent near-term revenue. As a clinical-stage company with no approved products, APRE's valuation is heavily driven by sentiment and anticipated catalysts rather than current fundamentals, leaving the shares vulnerable to sustained retracements.
What Drove APRE Stock Performance Over the Last Quarter
The trailing three months were defined by a sharp rise followed by an extended pullback. In late August, APRE advanced rapidly on heavy trading volume before peaking near $0.98 on a closing basis. That move coincided with a period of pipeline momentum, including an August 12 update noting accelerating enrollment in the ACESOT-1051 dose-escalation study and an August 28 announcement expanding the company's intellectual property portfolio to 28 issued and 30 pending patents.
Since that peak, the shares have drifted steadily lower, giving back most of the summer gains. The absence of new clinical data releases during the pullback, combined with the inherently high volatility of clinical-stage biotech, contributed to the downward pressure. The broader narrative remains centered on execution of the APR-1051 program, with investors weighing the promise of early partial responses reported earlier in 2026 against the timeline for the next data readout.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies appear in this section, helping users focus on tools that have demonstrated notable recent results. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to find approaches aligned with different objectives and risk profiles. For those interested in how automated systems are navigating current market conditions, the page offers a practical starting point for exploring data-driven trading strategies.
APRE Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring APRE should focus on several forward-looking factors. The most significant near-term catalyst is the anticipated Phase 1 data update from the ACESOT-1051 trial of APR-1051, expected at a medical meeting in the fourth quarter of 2026. Additional guidance on enrollment progress and expansion into uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer will be important. Updates on ATRN-119 combination approaches, including potential investigator-led studies, may also shape sentiment. As with all development-stage biotechs, funding and cash runway remain key considerations, as do broader market conditions affecting risk appetite for small-cap equities. These factors, rather than near-term price swings, will likely define the stock's direction in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
APRE in upward trend: price may jump up because it broke its lower Bollinger Band on November 10, 2026
APRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 43 cases where APRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APRE's RSI Oscillator exited the oversold zone, 40 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 71 cases where APRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for APRE just turned positive on November 03, 2026. Looking at past instances where APRE's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where APRE advanced for three days, in 150 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APRE as a result. In 86 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for APRE crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APRE entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.169) is normal, around the industry mean (3.498). P/E Ratio (-0.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. APRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry Biotechnology